Skip to content

Norwegian COgnitive Impairment After STroke (NorCOAST) Study

Norwegian COgnitive Impairment After STroke (NorCOAST) Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02650531
Acronym
Nor-Coast
Enrollment
816
Registered
2016-01-08
Start date
2015-05-31
Completion date
2018-10-08
Last updated
2022-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia, Mild Cognitive Impairment, Stroke

Keywords

Follow up studies, Risk factors

Brief summary

A prospective observational multicenter study aiming to describe incidence, and identify predictors for development of poststroke dementia (PSD) and mild cognitive impairment (MCI) after stroke

Detailed description

About 15000 Norwegians suffer a stroke every year and 2/3 will be more or less disabled. In addition to motor impairments and comorbidities, disability after stroke is often related to post stroke dementia (PSD) or mild neurocognitive disorder (NCD). However, these problems are hardly addressed in stroke or dementia research and frequently ignored in clinical practise. In the Nor-COAST study an interdisciplinary research group will collaborate to establish a research platform across all Norwegian Health Authorities. The overall aim of the study is to improve competence on PSD and NCD in order to improve individual health outcomes following a stroke. The specific objectives are to determine the incidence of PSD and NCD and the consequences on function and use of health care services and to enhance the early detection of PSD and NCD by identifying a set of risk factors, ranging from genetics to physical activity. The incidence and impact of PSD and NCD on function and use of health care services, medication and life-style changes are important when planning future health care services. Tools identifying patients at risk might improve diagnostic work up and together with knowledge on pathogenic aspects it will contribute to future treatment and prevention of PSD and NCD.

Interventions

None listed

Sponsors

Ullevaal University Hospital
CollaboratorOTHER
Vestre Viken Hospital Trust
CollaboratorOTHER
Haukeland University Hospital
CollaboratorOTHER
University Hospital of North Norway
CollaboratorOTHER
Norwegian University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Stroke diagnosis according to the WHO criteria

Exclusion criteria

* Not scandinavian speaking

Design outcomes

Primary

MeasureTime frameDescription
Score on the Montreal cognitive assessment (MOCA)18 monthsPerformance based test

Secondary

MeasureTime frameDescription
Score on the Montreal cognitive assessment (MOCA)3 monthsPerformance based test
Time spent in upright position3 monthsmeasured by bodyworn sensors
Brain Imaging18 monthsMRI
Score on Short Physical Performance Battery (sppb)3 monthsPerformance based test for mobility and lower extremity function
Selfreported habits concerning smoking, alcohol, diet and medication using standardised questionnaires3 months

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026